How Novartis is helping to eliminate leprosy

How Novartis is helping to eliminate leprosy
imberje1

/by
Novartis ianalumab receives FDA Breakthrough Therapy designation for Sjögren’s disease

Novartis ianalumab receives FDA Breakthrough Therapy designation for Sjögren’s disease
arcticnovartis

  • Designation based on clinical evidence supporting potential of ianalumab in Sjögren’s disease, including phase III trials1

  • Distinction expedites development and review of treatments for serious conditions that may demonstrate improvement over standard of care

  • Novartis plans to submit to health authorities globally starting in early 2026
/by
Novartis ianalumab receives FDA Breakthrough Therapy designation for Sjögren’s disease

Novartis ianalumab receives FDA Breakthrough Therapy designation for Sjögren’s disease
arcticnovartis

  • Designation based on clinical evidence supporting potential of ianalumab in Sjögren’s disease, including phase III trials1

  • Distinction expedites development and review of treatments for serious conditions that may demonstrate improvement over standard of care

  • Novartis plans to submit to health authorities globally starting in early 2026
/by
Letter to global governments: A call for bold life sciences investment

Letter to global governments: A call for bold life sciences investment
angilma1

/by
Novartis to add radioligand therapy manufacturing facility in Winter Park, Florida, fourth in US to serve patients and advance $23 billion investment

Novartis to add radioligand therapy manufacturing facility in Winter Park, Florida, fourth in US to serve patients and advance $23 billion investment
arcticnovartis

  • New 35,000-square-foot facility in Winter Park will expand RLT manufacturing footprint to optimize delivery for patients across southeastern US
  • Purpose-built facility will strengthen Novartis RLT manufacturing network alongside existing Indiana, New Jersey, and recently completed California sites
/by
2/25/2026 : Alcon’s Full-Year 2025 Earnings Call

View the live Webcast

/by
5/6/2026 : Alcon’s First-Quarter 2026 Earnings Call
/by
8/11/2026 : Alcon’s Second-Quarter 2026 Earnings Call
/by
11/11/2026 : Alcon’s Third-Quarter 2026 Earnings Call
/by
Novartis and US government reach agreement on lowering drug prices in the US

Novartis and US government reach agreement on lowering drug prices in the US
arcticnovartis

  • Novartis agrees to take actions aimed at meeting US Administration priorities for drug pricing
  • Additional Novartis medicines will be made available through direct-to-patient platforms in 2026
  • Company remains committed to investing in markets that value innovation and implement policies that support broad and fast access to medicines
/by